61st Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2020
- PDF / 12,897,272 Bytes
- 229 Pages / 595.276 x 790.866 pts Page_size
- 98 Downloads / 184 Views
ABSTRACTS
61st Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2020
Indian Society of Hematology and Blood Transfusion 2020
Contents Oral Abstract Papers 1. Acute Leukemia (Clinical) ....................................................... 1 2. Acute Leukemia (Laboratory) .................................................. 3 3. Anemia Including Hemolytic Anemia ..................................... 5 Bleeding Disorders ........................................................................ 8 5. Bone Marrow Failure and MDS (Clinical) .............................. 11 Bone Marrow Failure and MDS (Laboratory) ............................. 12 Infections and Support Care ......................................................... 12 Lymphoma and Myeloma (Clinical) ............................................ 13 Lymphoma and Myeloma (Laboratory) ....................................... 14 Miscellaneous (Laboratory Haematology).................................... 16 11. Myeloproliferative Neoplasm ................................................. 17 12. Stem Cell Transplantation ...................................................... 19 13. Thrombosis .............................................................................. 19 14. Transfusion Medicine.............................................................. 21 Poster Abstract Papers 1. Acute Leukemia (Clinical) ....................................................... 22 2. Acute Leukemia (Laboratory) .................................................. 28 ORAL Submission....................................................................... 154 Lymphoma and Myeloma (Laboratory) (ORAL-667) ............... 154
Oral Abstract Papers 1. Acute Leukemia (Clinical) Prognostic Value of Measurable Residual Disease After Venetoclax and Decitabine in Acute Myeloid Leukemia Abhishek Maiti*1, Courtney DiNardo1, Sa Wang2, Jeffrey Jorgensen2, Tapan Kadia1, Naval Daver1, Nicholas Short1, Musa Yilmaz1, Naveen Pemmaraju1, Gautam Borthakur1, Prithviraj Bose1, Ghayas C. Issa1, Alessandra Ferrajoli2, Elias J Jabbour2, Nitin Jain2, Guillermo GarciaManero2, Maro Ohanian2, Koichi Takahashi2, Guillermo MontalbanBravo2, Lucia Masarova2, Jan Burger2, Philip A. Thompson2, Srdan Verstovsek2, Koji Sasaki2, Michael Andreeff2, Caitlin R. Rausch2, Kathryn S. Montalbano2, Sherry Pierce2, Hagop Kantarjian1, Marina Konopleva1, Farhad Ravandi1
Department of Leukemia, 2The University of Texas MD Anderson Cancer Center, Houston, United States
1
Aims & Objectives: Measurable residual disease (MRD) has prognostic utility in acute myeloid leukemia (AML). However, the value of MRD after lower-intensity regimens is less established. We sought to evaluate the prognostic value of MRD after achievement of response with 10-day decitabine and venetoclax (DEC10-VEN). Patients/Materials & Methods: We conducted a post hoc analysis of a phase 2 trial to DEC-10-VEN (NCT03404193). MRD was assessed on bone marrow (BM) specimens using 8-color multiparametric flow cytometry (FCM)
Data Loading...
